Abstract
We investigated in an open, explanatory study a total of 24 patients meeting DSM-III-R criteria for schizophrenia. Eighteen patients were treated for at least 4 weeks with a fixed dose of orally administered haloperidol for at least 4 weeks (mean daily dosage ranging from 0.07 to 0.35 mg/kg b.w.), and 6 patients received haloperidol decanoate with a fixed dose for at least 4 months (dosage range 50–150 mg/4 weeks; calculated mean daily dosage ranging from 0.02 to 0.09 mg/kg b.w.). One week after injection of haloperidol decanoate, the single photon emission computed tomography examination was performed. Our data suggest that D2-dopamine-receptor occupancy of 50 mg/4 weeks haloperidol decanoate 1 week after injection corresponds to an oral dose of 4.5 mg/day haloperidol.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armitage P (1973) Statistical methods in medical research. Blackwell, Oxford, pp 269–281
Beresford R, Ward R (1987) Haloperidol decanoate: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drug 33:31–49
Brücke T, Podreka I, Angelberger P, Wenger S, Topitz A, Kufferle B, Muller C, Deecke L (1991) Dopamine DZ receptor imaging with SPELT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 11: 220–228
Brücke T, Roth J, Podreka L, Strobl R, Wenger S, Asenbaum S (1992) Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics. Lancet 339:497
Farde L, Nordström AL, Wiese FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central DI and DZ dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49: 538–544
Kung HF, Alavia A, Chang W, Kung MP, Keyes JW, Velchik MG, Billings J, Pan S, Noto R, Rausch A (1990) In vivo SPELT imaging of dopamine D2 receptors: initial studies with iodine123-IBZM in humans. J Nucl Med 31:573–579
Nyberg S, Farde L, Halldin CH, Dahl ML, Bertilsson L (1995) D2- dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 152(2):173–178
Rinne UK, Laihinen A, Rinne JO, Nagren K, Bergman J, Ruotsolainen U (1990) Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson’s disease. Movement Disord 5:55–59
Scherer J, Tatsch K, Oertel WH, Konjarczyk M, Albus M (1994) D2receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatr Scand 90:266–268
Scherer J, Tatsch K, Schwarz J, Oertel W, Kirsch MC, Albus M (1994) Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics. Biol Psychiatry 36: 627–629
Simpson GM, Angus JWS (1970) A rating scale for extra-pyramidal side effects. Acta Psychiatr Scand 45 (Suppl): 11–19
Tatsch K, Schwarz J, Oertel WH, Kirsch CM (1991) SPELT imaging of dopamine D2 receptors with 1231-IBZM: initial experience in controls and patients with Parkinson’s syndrome and Wilson’s disease. Nucl Med Commun 12:699–707
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scherer, J., Tatsch, K., Albus, M. et al. D2-dopamine-receptor occupancy during treatment with haloperidol decanoate. Eur Arch Psychiatry Clin Nuerosci 247, 104–106 (1997). https://doi.org/10.1007/BF02900201
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02900201